Keryx Biopharmaceuticals Surges on Prospects for Kidney Drug
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) are surging after the company said its experimental drug for kidney dialysis patients met its goal for effectiveness in a late-stage study. Keryx plans to seek US and European approval for the drug in the second quarter. Shares of Keryx jumped more than 40% to $4.82 in late-morning trading Monday. The stock is up 56% over the past 12 months. The New York-based company said its drug Zerenex met its study target for lowering phosphate levels in the blood of patients with kidney failure. Patients on Keryx’s drug showed a statistically significant reduction compared ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here